Key result
Low-molecular-weight heparin is a cornerstone for venous thromboembolism prophylaxis and treatment in cancer patients, potentially decreasing recurrence and imparting a survival benefit.
LMWH is a cornerstone for VTE prophylaxis and treatment in cancer patients, and pharmacists play a key role in managing anticoagulation.
Supports LMWH in cancer VTE; leaves open survival benefit confirmation and optimal regimens in prospective trials.
Clinicians must always maintain a heightened suspicion for the development of venous thromboembolism (VTE) in the cancer patient population. VTE is common in this population and often results in morbidity and mortality. The pathophysiology is complex and likely multifactorial. Risk factors for VTE include patient-associated, cancer-associated, and treatment-associated factors as well as biomarkers. Low-molecular-weight heparin (LMWH) is a cornerstone for VTE prophylaxis and treatment. Studies have shown that LMWH may decrease VTE recurrence and impart a survival benefit. Organizational guidelines are available to assist the clinician in choosing appropriate anticoagulant agents, dosing, and duration of prophylaxis and treatment. Pharmacists serve an important role for the safe and effective management of anticoagulation in this complex patient population. In addition, pharmacists can be important providers of patient education about VTE and anticoagulation.
No takes yet. Share an insight, caveat, or question.
Joanna Maudlin Pangilinan (2010) conducted a review in Venous Thromboembolism in Patients With Cancer. Low-molecular-weight heparin (LMWH) was evaluated. Low-molecular-weight heparin is a cornerstone for venous thromboembolism prophylaxis and treatment in cancer patients, potentially decreasing recurrence and imparting a survival benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: